Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Laser in ROP (RAINBOW)
NCT02375971Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in retinopathy of prematurity (ROP) (3 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at 24 weeks. Started Dec 2015; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT02375971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375971.